-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE: Glucocorticoids (corticosteroids) remain the mainstay of treatment for rheumatic diseases, but lead to reactivation of hepatitis B virus (HBV) in patients with remission of HBV infection .
Risk assessment and stratification are needed to guide the management of these patients prior to corticosteroid therapy .
Risk assessment and stratification are needed to guide the management of these patients prior to corticosteroid therapy .
Methods: A research team from the First Affiliated Hospital of Chongqing Medical University prospectively recruited patients with HBsAg-positive anti-hepatitis B core status with or without corticosteroids and calculated cumulative doses of prednisone and time-weighted average daily dose to determine corticosteroid exposure
.
The primary outcome was the composite time of HBV reactivation, hepatitis flare, or severe hepatitis
Methods: A research team from the First Affiliated Hospital of Chongqing Medical University prospectively recruited patients with HBsAg-positive anti-hepatitis B core status with or without corticosteroids and calculated cumulative doses of prednisone and time-weighted average daily dose to determine corticosteroid exposure
RESULTS: Among 1303 participants, the median cumulative and time-weighted mean doses of prednisone used in this cohort were 3000 mg ( IQR : 300-6750 mg ) and 15 mg/ day ( IQR : 10-20 , respectively) mg/ day)
Conclusions: Patients with a time-weighted mean prednisone dose greater than 20 mg/day would be classified as a high-risk group for HBV reactivation or hepatitis recurrence
Source:
Zhong Z, Liao W, Dai L , et al .
Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection.
Zhong Z, Liao W, Dai L , et al .
Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection.
Annals of the Rheumatic DiseasesPublished Online First: 21 December 2021.
doi: 10.
1136/annrheumdis- 2021-221650 , et al Annals of the Rheumatic Diseases Leave a comment here
